Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Summary

The purpose of this study is to found out if the drug IDH305 is safe and effective in subjects with IDH1 mutant grade II or III glioma that has progressed after observation or radiation therapy.

Timeline

Start

2018-04

Primary completion

2020-04

Completion

2020-04

Outcome

Outcome not reported

Stopped: “Novartis paused all study start-up activities due to safety evaluation of IDH305 compound.”

Drugs

Indications